Asuragen is a molecular diagnostics company using genomics to drive better patient management through best-in-class clinical testing solutions.
A carve-out of Ambion, Asuragen continues a legacy of leadership in the molecular diagnostics arena.
All of our molecular assays are designed to provide a streamlined workflow and ease of use. The current product portfolio includes qualitative assays enabling the detection of gene mutations often found in cytologic or histologic solid tumor specimens, such as KRAS or BRAF, and fusion transcripts or mutations associated with specific leukemia types or subtypes.
These assays incorporate Signature ® Technology which is optimized for the rapid multiplex analysis of nucleic acid sequences in a single reaction. Our oncology product offering also includes a multiplexed reverse transcription quantitative PCR assay to measure the expression levels of the BCR-ABL 1 fusion gene in white blood cells. In the area of genetics, Asuragen has introduced breakthrough PCR-based assays for molecular characterization of trinucleotide repeats and determination of methylation status in the 5’ region of the fragile X mental retardation (FMR1) gene.
Additionally, we offer a catalogue of molecular tools including reagents for specimen collection and nucleic acid stabilization and industry-leading controls and standard engineered using Asuragen’s patented Armored RNA ® technology.
Link to Asuragen